These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. Personeni N; Pressiani T; Bozzarelli S; Rimassa L World J Gastrointest Oncol; 2019 Oct; 11(10):788-803. PubMed ID: 31662820 [TBL] [Abstract][Full Text] [Related]
31. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513 [TBL] [Abstract][Full Text] [Related]
32. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962 [TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087 [TBL] [Abstract][Full Text] [Related]
36. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Bangaru S; Marrero JA; Singal AG Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082 [TBL] [Abstract][Full Text] [Related]
37. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533 [TBL] [Abstract][Full Text] [Related]
38. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Burgio V; Iavarone M; Di Costanzo GG; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Celsa C; Foschi FG; Silletta M; Amoruso DC; Rimini M; Bruccoleri M; Tortora R; Campani C; Soldà C; Viola MG; Forgione A; Conti F; Salani F; Catanese S; Giacchetto CM; Fulgenzi C; Coppola C; Lampertico P; Pellino A; Rancatore G; Cabibbo G; Ratti F; Pedica F; Della Corte A; Colombo M; De Cobelli F; Aldrighetti L; Cascinu S; Casadei-Gardini A Cancer Manag Res; 2021; 13():9379-9389. PubMed ID: 34992463 [TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874 [TBL] [Abstract][Full Text] [Related]
40. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. Chen YY; Wang CC; Liu YW; Li WF; Chen YH PeerJ; 2020; 8():e10382. PubMed ID: 33240675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]